Going beyond HRR mutations: A deep-learning approach on HRD detection in ovarian cancer
Going beyond HRR mutations: A deep-learning approach on HRD detection in ovarian cancer Homologous recombination deficiency (HRD) is an important prognostic and predictive biomarker in ovarian cancer. It is assessed by combining information from homologous...
Accelerating access to precision oncology with decentralized MSK solutions
SOPHiA GENETICS is collaborating with Memorial Sloan Kettering Cancer Center (MSK) to decentralize their advanced precision oncology tools – MSK-ACCESS® for liquid biopsy and MSK-IMPACT® for comprehensive genomic profiling (CGP). By combining the clinical expertise...
SOPHiA GENETICS and Karkinos Healthcare Forge Strategic Partnership to Advance Cancer Research in India
SOPHiA GENETICS technology helps advance cancer research across India SOPHiA GENETICS and Karkinos Healthcare join forces to propel cutting-edge genomic solutions for breakthroughs in personalized cancer care in India Boston, MA and Rolle, Switzerland, January 15,...
SOPHiA GENETICS Highlights Near-Term Growth Strategy at 42nd Annual J.P. Morgan Healthcare Conference
Strong SOPHiA DDM™ adoption and analysis volume contributes to continued revenue growth Liquid biopsy and HRD on SOPHiA DDM™ Platform continue to grow year-over-year, with Tennessee Oncology, Dasa and The Royal Marsden announced today Boston, MA and Rolle,...
Exactis Innovation and SOPHiA GENETICS Announce Collaboration on Multimodal Data Analytics
Boston, MA and Rolle, Switzerland, January 8, 2024 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced a collaboration with Exactis Innovation, based in Montreal, Quebec, who will contribute to...
Hôpital Saint-Louis Implements SOPHiA DDM™ Platform to Further Research of Myeloid Disorders
The Hospital will use SOPHiA GENETICS technology to streamline workflows and expedite research BOSTON and Rolle, Switzerland, December 21, 2023 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today...
The power of multimodal data-driven medicine
Capturing the complexity of human health and disease through machine learning analysis of multimodal data has the potential to drive the future of healthcare.
OmiCure® is Live on SOPHiA GENETICS
OmiCure uses the SOPHiA DDM™ Platform to advance its testing technology BOSTON, United States and Rolle, Switzerland, December 21, 2023 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that...
SOPHiA GENETICS to Present at the J.P. Morgan 2024 Healthcare Conference
BOSTON & ROLLE, Switzerland (December 14, 2023) --- SOPHiA GENETICS (NASDAQ: SOPH) today announced that Jurgi Camblong, PhD., Chief Executive Officer and Co-founder, is scheduled to present at the J.P. Morgan 2024 Healthcare Conference...
Optimized variant prioritization for enhanced insights: SOPHiA DDM™ and Alamut™ Visual Plus in action
Optimized variant prioritization for enhanced insights: SOPHiA DDM™️ and Alamut™️ Visual Plus in Action. Are you keen to improve your tertiary analysis? Discover how SOPHiA GENETICS end-to-end workflows can do just this. Our webinar covers: An intro to streamlined...
SOPHiA GENETICS Announces Expanded Suite of Liquid Biopsy Offerings
World-class liquid biopsy testing will be available to SOPHiA GENETICS customers Boston, MA and Rolle, Switzerland, December 7, 2023 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced an expanded...
The critical role of transcript analysis for refining the classification of variants associated with constitutional disorders
The critical role of transcript analysis for refining the classification of variants associated with constitutional disorders. Alamut™️ Visual Plus user presentation at the ASHG 2023 Annual Meeting. Presented by: Kai Lee Yap, PhD, FACMG,Director of Molecular...
Liquid biopsy analysis: Screening for clinically relevant information
Liquid biopsy is revolutionizing precision oncology with a non-invasive approach to tumor profiling. In this blog, we explore its clinical applications and why the right analytical technologies are needed when searching in a sea of genomic data.
SOPHiA GENETICS Announces Expansion of Work with CHU de Nîmes
Through the expanded relationship CHU de Nîmes will advance its research of rare and inherited diseases through pharmacogenomics BOSTON and Rolle, Switzerland, November 30, 2023 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in...
SOPHiA GENETICS Expands Relationship with Città della Salute e della Scienza di Torino
Largest health center in Italy uses SOPHiA DDM™ Platform on Microsoft Azure to expand data-driven medicine capabilities while ensuring accuracy and security BOSTON and ROLLE, Switzerland, November 28, 2023 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software...
